Huntington's disease alters neurons from development

March 21, 2017, University of Barcelona
Huntington’s disease alters neurons from development
UB researchers Mónica Pardo and Josep M.ª Canals participate in a study that opens a new door to the development of therapies for the first stages of the appearance of the Huntington disease’s symptoms.

Huntington's disease could alter neurons from when they start developing, according to a study conducted by the international HD iPSC Consortium. The study was published in the scientific journal Nature Neuroscience.

The study shows that the involved in the development of the stretchmark nucleus, the affected structure of the nervous system, are already altered during the process when are created. According to the researchers, these results could change treatments for the , which has no cure.

Huntington's disease is a progressive and irreversible neurodegenerative disease caused by the mutation of the gene that codifies the Huntington protein. This is a hereditary rare disease with only five-seven affected people (out of 100.000) in western countries.

According to Josep M. Canals, researcher at the Institute of Neurosciences of the University of Barcelona, "Despite being a genetic disease, it was thus far thought that the development of the nervous system of the was correct until the patient ages and some symptoms such as motor alterations (chorea, stiffness, etc.), cognitive deficiencies and psychiatric disorders start coming up. Our details show that there are subtle signs of alterations in the development of the neurons of these patients, which are not the same as normal neurons."

Study with iPSC cells from patients

The first phase of the study, led by the group of the UB, consisted of an analysis of during the striatal development in animal models, which was later compared to the gene expression of neurons from human iPSC . iPSCs are skin cells reprogrammed with transcription factors so that they function as similar to embryonic cells, with the ability to differentiate in any kind of specialized cell—in this case, neurons. This process enables studying the effects of genetic mutation in the cells affected by the disease.

When researchers crossed genic expression data, they detected that more than 600 genes responsible for development were altered in Huntington's patients' cells. Out of this list of altered genes, they selected the most important ones and then focused on a special pathway, the expression of which can be controlled with a drug: ISX-9 molecule. This drug was given in vitro to patient's cells and also to model mice with neuroprotective effects. "The drug reversed some of the markers: there was an increase of synapse and improvements at a cognitive level in model mice with the disease, which improved in memory tests" says Mónica Pardo, first author of the UB group.

"The results show that neurons in Huntington's patients, although they have the same function as normal neurons, are not totally the same and by acting on developing altered genes could reverse and lower symptoms," says Canals.

New view for the disease

According to the researchers, this study involves a change of the view on Huntington's disease evolution. "Instead of waiting for the symptoms to come up, maybe we should act on malfunctioning neurons before with drugs or inciting the activity of affected neurons like it is done in other diseases such as Parkinson," says Canals.

Among the current objectives of the HD iPSC Consortium is to widen the study with a wider range of patients in order to find out which genes are systematically and uniformly altered among them. Therefore, new precise therapeutic targets can be established in order to create new drugs to treat the disease.

Explore further: Cellular quality control process could be Huntington's disease drug target

More information: Ryan G Lim et al. Developmental alterations in Huntington's disease neural cells and pharmacological rescue in cells and mice, Nature Neuroscience (2017). DOI: 10.1038/nn.4532

Related Stories

Cellular quality control process could be Huntington's disease drug target

February 13, 2017
The loss of motor function and mental acuity associated with Huntington's disease might be treatable by restoring a cellular quality control process, which Duke Health researchers have identified as a key factor in the degenerative ...

ALS research suggests stem cells be 'aged' to speed progress toward finding treatments

July 19, 2016
Cedars-Sinai scientists are seeking to build an improved stem-cell model of amyotrophic lateral sclerosis (ALS) to accelerate progress toward a cure for the devastating neurological disorder. Their findings demonstrate that ...

Potential therapeutic target for Huntington's disease

August 16, 2016
There is new hope in the fight against Huntington's disease. Scientists at the Gladstone Institutes discovered that changing a specific part of the huntingtin protein prevented the loss of critical brain cells and protected ...

Research may provide missing link in search for Parkinson's disease therapeutics

May 19, 2016
Parkinson's disease (PD), a chronic, progressive and devastating neurodegenerative motor disease affecting as many as one million Americans, is complex. Its causes likely include a combination of genetic, environmental and ...

Huntington's disease linked to dysfunction of brain structure

December 21, 2016
Northwestern Medicine scientists identified a link between Huntington's disease and dysfunction of the subthalamic nucleus, a component of the basal ganglia, a group of brain structures critical for movement and impulse control.

Defect in process that controls gene expression may contribute to Huntington's disease

August 15, 2016
A protein complex called Polycomb Repressive Complex 2 (PRC2), which plays a critical role in forming specific classes of nerve cells in the brain during development, also plays an important role in the adult brain where ...

Recommended for you

Researchers target immune cells to slow progression of Amyotrophic Lateral Sclerosis

March 22, 2018
New research into Amyotrophic Lateral Sclerosis (ALS) - also known as motor neuron disease - shows that specific immune cells may help slow progression of the disease, an important step towards developing new therapies to ...

Focus on early stage of illness may be key to treating ALS, study suggests

March 22, 2018
A new kind of genetically engineered mouse and an innovation in how to monitor those mice during research have shed new light on the early development of an inherited form of amyotrophic lateral sclerosis (ALS).

Flow of spinal fluid disrupted in inherited developmental disorder

March 22, 2018
Scientists have pinpointed the mechanism behind hydrocephalus, an accumulation of cerebrospinal fluid around the brain, in an inherited developmental disorder called Noonan syndrome.

Obesity trigger identified within the human gut

March 22, 2018
The key chemical for happiness and sadness, serotonin, is also a force in our body's weight gain and calorie control, and scientists say more research could reduce obesity rates.

New wearable brain scanner allows patients to move freely for the first time

March 21, 2018
A new generation of brain scanner, that can be worn like a helmet allowing patients to move naturally whilst being scanned, has been developed by researchers at the Sir Peter Mansfield Imaging Centre, University of Nottingham ...

International team confirms new genetic mutation link to amyotrophic lateral sclerosis

March 21, 2018
Kinesin family member 5A (KIF5A), a gene previously linked to two rare neurodegenerative disorders, has been definitively connected to amyotrophic lateral sclerosis (ALS) by an international team from several of the world's ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

not rated yet Mar 21, 2017
stretchmark nucleus?

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.